Fisher Asset Management LLC cut its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 10,910,669 shares of the company’s stock after selling 52,425 shares during the period. Fisher Asset Management LLC owned about 0.43% of Novo Nordisk A/S worth $453,775,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in NVO. Advisory Services Network LLC increased its stake in Novo Nordisk A/S by 28.8% in the second quarter. Advisory Services Network LLC now owns 2,238 shares of the company’s stock valued at $120,000 after buying an additional 500 shares during the last quarter. J.Safra Asset Management Corp purchased a new stake in Novo Nordisk A/S during the second quarter valued at $127,000. Ranger International Management LP increased its stake in Novo Nordisk A/S by 49.1% in the second quarter. Ranger International Management LP now owns 2,430 shares of the company’s stock valued at $131,000 after buying an additional 800 shares during the last quarter. Cribstone Capital Management LLC purchased a new stake in Novo Nordisk A/S during the second quarter valued at $159,000. Finally, Tower Research Capital LLC TRC increased its stake in Novo Nordisk A/S by 2,998.0% in the second quarter. Tower Research Capital LLC TRC now owns 3,098 shares of the company’s stock valued at $167,000 after buying an additional 2,998 shares during the last quarter. Hedge funds and other institutional investors own 7.14% of the company’s stock.

Institutional Ownership by Quarter for Novo Nordisk A/S (NYSE:NVO)

Novo Nordisk A/S (NYSE:NVO) traded down 0.52% during trading on Monday, hitting $32.25. 3,988,373 shares of the stock traded hands. The company’s 50 day moving average price is $37.86 and its 200 day moving average price is $48.09. Novo Nordisk A/S has a 12 month low of $32.19 and a 12 month high of $59.00. The company has a market cap of $81.48 billion, a P/E ratio of 14.96 and a beta of 0.84.

Several research firms recently weighed in on NVO. DNB Markets downgraded Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, October 31st. HSBC reiterated a “hold” rating on shares of Novo Nordisk A/S in a report on Thursday, October 13th. Citigroup Inc. downgraded shares of Novo Nordisk A/S from a “buy” rating to a “neutral” rating in a report on Monday, October 31st. Zacks Investment Research downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a report on Tuesday, September 6th. Finally, Bank of America Corp. downgraded shares of Novo Nordisk A/S from a “neutral” rating to an “underperform” rating in a report on Friday, October 28th. Two equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $61.33.

About Novo Nordisk A/S

Novo Nordisk A/S is a healthcare company. The Company is engaged in discovery, development, manufacturing and marketing of pharmaceutical products. The Company’s business segments include diabetes and obesity care, and biopharmaceuticals. The diabetes and obesity care segment covers insulins, glucagon-like peptide-1 (GLP-1), other protein-related products (such as glucagon, protein-related delivery systems and needles), oral anti-diabetic drugs and obesity.

5 Day Chart for NYSE:NVO

Receive News & Stock Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related stocks with our FREE daily email newsletter.